Incremental Prognostic Value of Cardiac Magnetic Resonance Beyond Biomarker Staging in Transthyretin Cardiac Amyloidosis

Clicks: 1
ID: 319270
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #94 of 96 articles by views in European Heart Journal - Cardiovascular Imaging

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
AIMS: While cardiac magnetic resonance (CMR) provides prognostic value in transthyretin cardiac amyloidosis (ATTR-CA), current ATTR-CA staging relies on serum biomarkers. We evaluated the incremental value of incorporating CMR parameters into the National Amyloidosis Center (NAC) staging and assessed their utility in guiding evaluation for advanced heart failure (HF) therapies and emerging disease-modifying treatments. METHODS AND RESULTS: We retrospectively analyzed a multicenter cohort of 266 ATTR-CA patients who underwent CMR between 2007-2023. Cox regressions were used to assess time to death. A baseline model was constructed using the NAC stage. CMR predictor variables were selected a priori based on clinical relevance and non-collinearity, then refined using stepwise backward elimination regression with NAC stage control; variables retained in ≥60% of 1,000 bootstrapped samples were included. Internal validation was performed via bootstrapping, with performance reported as Harrell's C-statistic and calibration slope. Decision curve analysis evaluated clinical utility.85 patients (32%) died over a median follow up of 20 months (IQR 8-35). Extracellular volume (ECV ≥59%, HR 2.45, 95% CI 1.2-5.2, p = 0.020) and indexed left atrial volume (LAVi ≥54 ml/m2, HR 2.00, 95% CI 1.1-3.7, p = 0.026) were independently associated with mortality after NAC adjustment and improved prognostic accuracy across all biomarker stages. When risk prediction was framed around initiation of advanced HF or emerging disease-modifying therapies, incorporating CMR alongside NAC staging facilitated identification of 28 additional high-risk patients per 1,000. CONCLUSION: CMR-derived ECV and LAVi were associated with incremental prognostic value in ATTR-CA beyond biomarker staging and may inform clinical risk stratification.
Reference Key
openalex_W7166799797 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Tommy Chiou, Iva Minga, Varun Subashchandran, Cristiane C Singulane, Amit R. Patel, Karolina M Zareba, Lu Ey, Akash Goyal, Jai Singh, Michael D. Elliott, Vidya Nadig, Fernandes Fr, Marcelo L Vieira, Shaimaa Fadl, Cory Trankle, Dipan J. Shah, El‐Moatasem Gabr, Maria Poonawalla, Franklin Mirales, N Sarswat, Amit Pursnani, Hena Patel, Karima Addetia, Jeremy Slivnick
Journal European Heart Journal - Cardiovascular Imaging
Year 2026
DOI
10.1093/ehjci/jeag170
URL
https://doi.org/10.1093/ehjci/jeag170
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.